ABSTRACT NUMBER: ESOC2026A1930 EFFICACY AND SAFETY OF INDOBUFEN VERSUS ASPIRIN IN ACUTE ISCHEMIC STROKE PATIENTS. A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Rashad G Mohamed, Amir Hegazi, Mohamed Ehab Eldesoky, Khalid Sarhan, Magdy Shehab, Mostafa Meshref · 2026
Read ABSTRACT NUMBER: ESOC2026A1930 EFFICACY AND SAFETY OF INDOBUFEN VERSUS ASPIRIN IN ACUTE ISCHEMIC STROKE PATIENTS. A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS by Rashad G Mohamed, Amir Hegazi, Mohamed Ehab Eldesoky, Khalid Sarhan, Magdy Shehab, Mostafa Meshref (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13146096.txt.
Description
Rashad G Mohamed and co-authors present a 2026 conference review weighing a newer clot drug against aspirin in acute stroke. Aspirin is the standard early drug, while the newer one may offer a gentler safety face. Head-to-head trial proof stayed thin, so the team pooled the trials.
Four trials with near fifty-nine hundred patients fed the pool. Function and nerve scores at ninety days matched between the drugs. Repeat stroke within three months, though, ran clearly higher on the newer drug. Heavy bleeding and brain bleeding leaned lower on the newer drug, but not by a firm margin. The authors call for larger trials before any switch in standard care.
Catalog record
| CREATOR | Rashad G Mohamed, Amir Hegazi, Mohamed Ehab Eldesoky, Khalid Sarhan, Magdy Shehab, Mostafa Meshref |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |